BRPI0917518A2 - formulações de canfosfamida e suas preparações - Google Patents

formulações de canfosfamida e suas preparações

Info

Publication number
BRPI0917518A2
BRPI0917518A2 BRPI0917518A BRPI0917518A BRPI0917518A2 BR PI0917518 A2 BRPI0917518 A2 BR PI0917518A2 BR PI0917518 A BRPI0917518 A BR PI0917518A BR PI0917518 A BRPI0917518 A BR PI0917518A BR PI0917518 A2 BRPI0917518 A2 BR PI0917518A2
Authority
BR
Brazil
Prior art keywords
camphosphamide
formulations
preparations therefor
therefor
preparations
Prior art date
Application number
BRPI0917518A
Other languages
English (en)
Inventor
Betsy R Hughes
Original Assignee
Telik Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Telik Inc filed Critical Telik Inc
Publication of BRPI0917518A2 publication Critical patent/BRPI0917518A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/664Amides of phosphorus acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0917518A 2008-08-28 2009-08-04 formulações de canfosfamida e suas preparações BRPI0917518A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9258008P 2008-08-28 2008-08-28
PCT/US2009/052694 WO2010025011A1 (en) 2008-08-28 2009-08-04 Formulations of canfosfamide and their preparation

Publications (1)

Publication Number Publication Date
BRPI0917518A2 true BRPI0917518A2 (pt) 2015-11-17

Family

ID=41168726

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0917518A BRPI0917518A2 (pt) 2008-08-28 2009-08-04 formulações de canfosfamida e suas preparações

Country Status (17)

Country Link
US (2) US20100056825A1 (pt)
EP (1) EP2328591A1 (pt)
JP (1) JP2012501331A (pt)
KR (1) KR20110060898A (pt)
CN (1) CN102123714A (pt)
AR (1) AR073074A1 (pt)
AU (1) AU2009286010A1 (pt)
BR (1) BRPI0917518A2 (pt)
CA (1) CA2733548A1 (pt)
CL (1) CL2011000439A1 (pt)
IL (1) IL211039A0 (pt)
MX (1) MX2011001867A (pt)
NZ (1) NZ591213A (pt)
RU (1) RU2011109921A (pt)
TW (1) TW201008599A (pt)
WO (1) WO2010025011A1 (pt)
ZA (1) ZA201101214B (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100056825A1 (en) 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
US8324426B2 (en) 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation
WO2012115655A1 (en) * 2011-02-25 2012-08-30 Telik, Inc. Formulations of canfosfamide and their preparation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4931441A (en) 1988-11-09 1990-06-05 Luitpold Pharmaceuticals, Inc. Stabilized aqueous leucovorin calcium compositions
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
AU3184300A (en) 1999-03-19 2000-10-09 Ranbaxy Laboratories Limited Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil
JP4816083B2 (ja) 2003-08-08 2011-11-16 小野薬品工業株式会社 短時間型β遮断薬を有効成分とする心拍数減少剤
US8198247B2 (en) * 2004-12-21 2012-06-12 Telik, Inc. Process for and intermediates in the preparation of canfosfamide and its salts
WO2007027941A2 (en) 2005-08-31 2007-03-08 Abraxis Bioscience, Llc. Compositions and methods for preparation of poorly water soluble drugs with increased stability
US20100056825A1 (en) 2008-08-28 2010-03-04 Telik, Inc. Formulations of canfosfamide and their preparation
US8324426B2 (en) 2008-08-28 2012-12-04 Telik, Inc. Formulations of canfosfamide and their preparation

Also Published As

Publication number Publication date
AU2009286010A1 (en) 2010-03-04
CA2733548A1 (en) 2010-03-04
US20110224175A1 (en) 2011-09-15
NZ591213A (en) 2012-11-30
JP2012501331A (ja) 2012-01-19
IL211039A0 (en) 2011-04-28
WO2010025011A8 (en) 2010-09-30
EP2328591A1 (en) 2011-06-08
CL2011000439A1 (es) 2011-07-15
AR073074A1 (es) 2010-10-13
CN102123714A (zh) 2011-07-13
US20100056825A1 (en) 2010-03-04
WO2010025011A1 (en) 2010-03-04
ZA201101214B (en) 2013-07-31
TW201008599A (en) 2010-03-01
US8481781B2 (en) 2013-07-09
KR20110060898A (ko) 2011-06-08
RU2011109921A (ru) 2012-10-10
MX2011001867A (es) 2011-04-07

Similar Documents

Publication Publication Date Title
BRPI0914155A2 (pt) preparações de xampu
DK2068886T3 (da) Lipidholdige præparater
BRPI0912213A2 (pt) preparação cosmética
BRPI0907231A2 (pt) pirrolpirimidinas e pirrolpiridinas
BRPI0908785A2 (pt) Formulações herbicida
BRPI0814003A2 (pt) Formulações de anticorpo
BRPI0814252A2 (pt) Formulações de anticorpo
BRPI0820381A2 (pt) Formulações farmacêuticas
BRPI0919552A2 (pt) Formulações de glifosato contendo surfactantes e amidoalquilamina
BRPI1012533A2 (pt) composto de piradazinona e uso do mesmo
DK2066354T3 (da) Norovirus vaccine formuleringer
BRPI0914152A2 (pt) preparações de xampu
BRPI0909770A2 (pt) Vacina, e, kit
BRPI0814188A2 (pt) Formulações
BRPI0822221A2 (pt) Composições aquosas e estáveis de ciclosporina
BR112012005389A2 (pt) preparações pesticidas
BRPI0921654A2 (pt) formulação farmacêutica
BRPI0921947A2 (pt) formulações de proteína terapêutica
DE112008003934A5 (de) Kosmetikmaske
BRPI0908455A2 (pt) formulações de flibanserina
BRPI0910570A2 (pt) uso de bioconjugados, e, formulações farmacêuticas
BRPI1008147A2 (pt) composição de xampu concentrado e xampu centrado
ATE520307T1 (de) Stabilisierte malathion-mikrokapselformulierungen
FR2915896B1 (fr) Composition cosmetique foisonnee
BRPI0823402A2 (pt) Formulações farmacêuticas de olmesartan

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2370 DE 07-06-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.